Syndicated Research Studies

Glioblastoma Multiforme (GBM) Treatment Market Summary The global glioblastoma multiforme (GBM) treatment market was valued at USD 3.72 billion in 2024 and is expected to reach USD 7.87 billion by 2033, expanding at a CAGR of 8.68% from 2025 to 2033. Market growth is primarily driven by the rising prevalence of GBM and the substantial clinical burden associated with this aggressive brain cancer. GBM incidence is increasing globally due to improved diagnostic capabilities and a notable rise in actual case numbers. The growing aging population further intensifies this trend, as the risk of developing GBM increases significantly with age. As geriatric populations expand worldwide, healthcare systems face mounting challenges, reinforcing the critical need for more effective therapies and advanced care strategies. Recent data from leading healthcare institutions underscore the escalating burden of GBM. In December 2024, Parkway Cancer Centre in Singapore reported nearly 100 new GBM case...

Glioblastoma Multiforme Treatment Industry Overview The global glioblastoma multiforme treatment market size was valued at USD 2.14 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.8% from 2021 to 2028. The growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios are among the factors anticipated to fuel the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period. The increasing incidence of brain tumors is expected to boost the growth of the market over the forecast period. According to Global Cancer Observatory, in 2020, the incidence of brain and CNS cancers was 308,102 globally and the number of deaths was 251,329 worldwide. Brain cancer is one of the deadliest forms of cancer. Gather more insights about the market drivers, restrains and growth of the Global Glioblastoma Multiforme Trea...